1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Marksans Pharma Limited

Marksans Pharma Limited

MARKSANS.BO
Marksans Pharma LimitedIN flagBombay Stock Exchange
268.00
INR
+6.95
- -
121.59BMarket Cap
Marksans Pharma Limited
MARKSANS.BO
(Bombay Stock Exchange)

Recent

price

268.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
8.28
9.67
11.38
16.31
19.46
21.58
18.54
22.09
24.12
27.59
33.43
36.16
44.53
47.98
57.89
65.11
65.19
Revenue per Share
-0.04
-4.86
1.19
1.87
2.67
1.92
0.22
0.87
1.97
2.95
5.83
4.51
6.41
6.92
8.4
9.22
9.23
Basic EPS, GAAP
-1.42
-1.84
1
1.55
2.88
-2.47
-0.33
1.22
0.67
4.24
3.23
1.29
4.42
0.48
0.74
7.23
- -
Free Cash Flow per Basic Share
- -
0.01
0.12
0.27
0.17
0.44
0.42
0.06
0.11
0.72
0.1
0.26
0.24
0.5
0.6
0.8
- -
Dividend per Share
1.37
-8.33
-6.84
-5.59
-2.42
-1.17
-1.41
-0.69
1.07
3.08
9.18
13.44
19.81
24.59
32.39
1
1
Book Value per Share
-7.27
-6.9
0.3
1.61
7.62
8.5
7.97
9.46
11.75
14.08
20.48
27.71
39.86
43.73
52.44
63.78
63.86
Tangible Book Value per Share
368
368
385
385
409
409
409
409
409
409
409
409
415
453
453
453
453
Basic Weighted Avg Shares
3,046
3,555
4,384
6,285
7,967
8,833
7,588
9,041
9,873
11,293
13,684
14,801
18,496
21,742
26,228
29,509
29,509
Sales/Revenue/Turnover
-30.64
-34.72
12.46
15.64
20.06
11.81
0.37
5.71
11.07
14.67
23.29
14.64
16.92
17.82
17.13
17.02
17.02
Operating Margin (%)
2
237
156
157
161
281
301
268
228
267
362
448
519
743
834
986
986
Depreciation Expense
-14
-1,788
459
719
1,094
785
88
358
804
1,208
2,385
1,846
2,663
3,137
3,806
4,179
4,179
Net Income, GAAP
- -
- -
- -
14.8
28.18
22.56
23.92
28.11
22.88
23.17
21.06
24.52
21.42
25.65
24.08
25.06
25.06
Effective Tax Rate (%)
-0.46
-50.3
10.47
11.44
13.73
8.89
1.16
3.96
8.15
10.69
17.43
12.47
14.4
14.43
14.51
14.16
14.16
Profit Margin (%)
-3,104
-3,036
-534
238
2,226
1,891
1,878
2,159
2,988
3,648
6,039
8,450
13,343
14,726
17,268
21,956
21,956
Working Capital
190
152
79
198
- -
- -
- -
- -
- -
75
93
414
657
1,900
2,633
2,701
2,701
LT Debt
-626
-1,625
935
1,488
3,879
4,532
4,397
4,804
5,527
6,491
9,054
12,230
17,651
20,859
24,894
30,527
30,527
Total Equity
- -
- -
- -
28.58
26.07
15.04
0.39
6.35
13.23
18.88
29.77
13.83
14.9
13.4
13.05
11.94
11.94
Return on Invested Capital (%)
- -
- -
- -
-146.16
322.62
172.59
15.93
44.61
67.01
77.1
80.75
33.57
33
27.36
24.28
38.91
38.91
Return on Capital (%)
-2.76
- -
- -
- -
- -
- -
- -
- -
- -
142.1
95.05
39.86
38.79
32.39
29.48
55.25
55.25
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
659
- -
732
LT Borrowings
- -
- -
- -
LT Finance Leases
2,662
- -
2,701
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
453
- -
453
Market Capitalization
74,694
81,535
71,135

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
23,542
- -
27,227
Cash, Cash Equivalents & STI
6,713
- -
9,946
Accounts Receivable, Net
6,031
- -
6,446
Inventories
9,552
- -
9,723
Total Current Liabilities
4,546
- -
5,271
Payables & Accruals
- -
- -
- -
ST Debt
659
- -
732
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.78%
27.91%
22.63%
Free Cash Flow
93.78%
205.25%
870.8%
Net Income, GAAP
55.93%
14.12%
9.81%
Sales/Revenue/Turnover
13.36%
16.77%
12.51%
Total Cash Common Dividend
79.83%
66.15%
33.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,000
5,312
5,861
5,568
21,742
2025
5,906
6,419
6,818
7,085
26,228
2026
6,200
7,204
7,544
8,561
29,509

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.52
1.84
1.84
- -
6.92
2025
1.96
2.13
2.31
2
8.4
2026
1.29
2.17
2.5
3.27
9.22

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.5
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
0.8
Similar Companies
Citius Oncology, Inc. (CTOR)
Aurora Optoelectronics Co.,Ltd. (600666.SS)
Oscotec Inc. (039200.KQ)
Grifols, S.A. (GIFLF)
BioDelivery Sciences Intl, Inc. Wrrt (BDSIW)
Daiichi Sankyo Company, Limited (DSNKY)
Business
Marksans Pharma Limited is an India-based pharmaceutical company engaged in the development, manufacture, and marketing of pharmaceutical formulations primarily for the treatment of central nervous system disorders, pain management, gastrointestinal conditions, cardiovascular diseases, and anti-infective therapies. Its product portfolio includes tablets, capsules, oral liquids, ointments, dry syrups, and injections marketed under various brands. The company operates in domestic and international markets, with a strong presence in regulated and semi-regulated pharmaceutical markets across the United States, Europe, Africa, and Asia. Founded in 1990, Marksans Pharma is headquartered in Mumbai, Maharashtra, India. The company focuses on manufacturing and supplying branded and generic formulations, contract manufacturing, and active pharmaceutical ingredients (APIs). Marksans Pharma's diversified product segments cover therapeutic categories such as neurology, analgesics, gastroenterology, cardiovascular, and anti-infectives, targeting hospitals, pharmacies, and institutional customers. It also has subsidiaries engaged in pharmaceutical marketing and distribution that extend its geographic reach. In the last 1-2 years, Marksans Pharma has pursued strategic expansions including new product launches and broadening its international footprint, particularly reinforcing its presence in regulated markets like the US and Europe. It has enhanced its contract manufacturing capacities and entered into partnerships to support pipeline development and accelerate marketing efforts. These moves illustrate a strategic shift towards strengthening high-growth, regulated market operations while maintaining diversified geographical and therapeutic profiles. The company continues to leverage its manufacturing capabilities and product development expertise to expand its branded and generic pharmaceutical offerings globally.